Biotech financing
25WmEet
25WmEet
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Biotech</strong> <strong>financing</strong>: United States<br />
Top US venture <strong>financing</strong>s, 2015<br />
Company Region Lead product clinical stage Therapeutic focus<br />
Amount<br />
(US$m)<br />
Month<br />
Boston Pharmaceuticals* New England Preclinical Multiple 600 November<br />
ModeRNA Therapeutics New England Phase I Multiple 450 January<br />
Intarcia Therapeutics San Francisco Bay Area Phase III Diabetes 300 April<br />
Stemcentrx San Francisco Bay Area Phase I Oncology 250 August<br />
Denali Therapeutics* San Francisco Bay Area Preclinical Neurology 217 May<br />
Adaptive <strong>Biotech</strong>nologies Pacific Northwest Preclinical Oncology 195 May<br />
Humacyte North Carolina Phase II Regenerative medicine 150 October<br />
Editas Medicine New England Preclinical Multiple 120 August<br />
23andMe San Francisco Bay Area Development Multiple 115 June<br />
PaxVax San Diego Marketed Infectious disease 105 December<br />
Gritstone Oncology* San Francisco Bay Area Preclinical Oncology 102 October<br />
Stemcentrx San Francisco Bay Area Phase I Oncology 100 January<br />
Nantibody* San Diego Preclinical Oncology 100 March<br />
Adaptive <strong>Biotech</strong>nologies Pacific Northwest Services, technologies and tools Oncology 96 January<br />
Allergen Research San Francisco Bay Area Phase III Allergies 80 March<br />
Source: EY, Capital IQ and VentureSource.<br />
*First venture round<br />
The top US venture <strong>financing</strong>s of the year feature several<br />
companies — and investors — that are far from traditional.<br />
These include Boston Pharmaceuticals with its specialty pharma<br />
approach, Moderna Therapeutics with its several-companiesunder-one-umbrella<br />
structure, and Intarcia Therapeutics,<br />
which created a diabetes drug-device hybrid. Another company<br />
that made headlines in 2015: Stemcentrx, an oncology stem<br />
cell developer that has five therapies in the clinic and raised<br />
US$350 million in two rounds.<br />
Although these outliers may sit at the top of the chart, they<br />
hardly tell the year’s whole story. Thirteen venture rounds<br />
topped the US$100 million mark in 2015, compared with five<br />
in 2014. In all, there were 26 venture rounds that each raised at<br />
least US$70 million in 2015, versus only 10 in 2014 and three<br />
in 2013. Oncology-focused biotechs garnered six of the top 15<br />
venture rounds. Reflecting a penchant for investors to “go big”<br />
in early rounds this past year, five of the top 15 venture rounds<br />
were for first-round <strong>financing</strong>s.<br />
16 Beyond borders 2016 — <strong>Biotech</strong> <strong>financing</strong>
Change language